Morgan Stanley analyst Hamza Fodderwala maintains Rapid7 (NASDAQ:RPD) with a Equal-Weight and lowers the price target from $55 to $44.
Where ChemoCentryx Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
